Kestra Rides a High-Margin Wave: Record Quarter, Fortified Balance Sheet, and a Bullish FY27

Kestra caps FY26 with 66% revenue growth, 10th straight quarter of gross margin expansion, and a new term loan to fund market share gains in the underpenetrated WCD category.

KMTS · Earnings Call · 2026-07-14

Strong close to a foundational year

Kestra Medical Technologies finished fiscal 2026 on a high note, posting $28.6 million in Q4 revenue (up 66% YoY) and a gross margin of 54.8% — the company's 10th consecutive quarter of sequential margin expansion. For the full year, revenue reached $95 million (up 59%), while gross margin climbed to 51.4%, up ~11 points. The heart failure narrative continues to resonate: management highlighted the ACE-PAS study and a new Heart Rhythm publication that positions WCDs as a potential strategy for patients not yet eligible for an ICD. "The paper further identifies WCDs as potential strategy to reduce sudden cardiac death in patients not yet eligible for an ICD," said CEO Brian Webster.

Investment pays off, but the bill is larger

The fiscal year was defined by purposeful investment — the commercial team expanded from ~80 to 130 sales territories, and the company built out revenue cycle management capabilities. That investment is now showing up in the P&L: the conversion rate improved to ~46% (up >2 points YoY per Vaseem), and management expects that to keep marching higher. On the call, CFO Vaseem Mahboob noted, "our operating cash burn declined by $5 million... we will continue to invest in 2027 but maybe not at the same pace in 2026." Indeed, free cash flow (less SBC) landed at -$38M for the latest quarter, a notable improvement versus the $54M burn in the prior-year period.

Guidance: confidence without overpromising

For fiscal 2027, management guided to $137 million in revenue, a 44% increase. Analysts pressed on whether the guide is too conservative given the momentum and the newly funded balance sheet. Brian Webster pushed back gently: "I think 44% growth as an initial guide is pretty darn fantastic." The company also announced a new $200 million term loan facility with Pharmakon, a non-dilutive structure that frees up cash for further investment and potential M&A. "This nondilutive financing... fortifies our balance sheet, reduces our cost of capital, and provides significant financial flexibility," said Vaseem.

We are still in the early innings of market and we see this category growing into a multibillion dollar market in the years ahead.
Brian Webster · 2026-07-14

Competitive dynamics and the warning letter

One of the more interesting threads on the call was the discussion of a regulatory warning letter received by the primary competitor (ZOLL) in June, focused on AEDs and ventilators. Brian acknowledged the situation: "Anytime there is regulatory actions in the industry, you would be wise to pay attention," but noted it was directed at a different division. He argued that the competitor's new WCD product is "incremental, not transformative" and would take 3-5 years to roll out given the fleet-based model. This gives Kestra a window to keep taking share — and with the new algorithm now shipping to all patients, the product differentiation is sharper than ever. In the Q&A, Brian also touched on the recent Heart Rhythm Society publication as a catalyst: "It is going to be a journey. The papers like this are the start of that journey." (He had earlier noted in the prior quarter's call that "our conversion rate... will be approximately 49%," underscoring the steep progress in revenue cycle management.) The company's territory coverage, as he explained last September, was "a little over 50% of the U.S." — a gap it has since closed further, reinforcing the growth runway.

Market outlook and the path to 70% margins

Management reiterated confidence in reaching 70%+ gross margins over the next few years, driven by volume leverage, in-network mix, and cost improvement projects. The WCD market is estimated to have grown in the low-to-mid teens, and Kestra is targeting ~4-5 points of share gain per year. With ~70% geographic coverage today and plans to add ~40 more territories, the runway remains long. The stock sits near its all-time high, up ~51% over the last 90 days, reflecting investor confidence in the story. With a fortified balance sheet, accelerating revenue growth, and a clear catalyst pipeline, Kestra has arguably never been in a stronger position. The key risk remains execution — can the company deliver on its guidance while absorbing new reps and managing the transition to higher margins? As Brian closed the call, "We are looking forward to a really strong f y 2027."